Results 101 to 110 of about 52,949 (209)

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

Case Report Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib [PDF]

, 2020
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic ...
Yoshihiro Nishimura, Daisuke Kasai, Kazuyuki Kobayashi, Yukihisa Hatakeyama, Suya Hori, Yoshikazu Kotani, Tatsuya Nagano, Yasuhiro Funada, Masahiro Katsurada, Daisuke Tamura   +9 more
core  

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy

, 2015
Perrine Capmas,1 Hervé Fernandez21Inserm, Centre of Research in Epidemiology and Population Health (CESP), 2Department of Gynecology, Bicetre Hospital, GHU Sud, AP-HP, Le Kremlin Bicêtre, FranceAbstract: Medical management for ectopic ...
Fernandez H, Capmas P
core  

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, Volume 37, Issue 5, Page 752-760, October 2026.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source

Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance

, 2015
Xiwei Yu,1,* Guang Yang,2,* Yijie Shi,1 Chang Su,3 Ming Liu,1 Bo Feng,1 Liang Zhao1 1School of Pharmacy, Liaoning Medical University, Jinzhou, People’s Republic of China; 2Department of Oncology, BenQ Medical Center, Nanjing Medical University ...
Yang G, Shi YJ, Su C, Zhao L, Liu M, Yu XW, Feng B   +6 more
core  

Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing Atp-Binding Cassette Family Protein

, 2009
Gefitinib inhibits the ATP-binding site of the tyrosine kinase associated with the epidermal growth factor receptor. It is conceivable that gefitinib may inhibit functions of ATP-binding cassette (ABC) transporters by binding at their ATP-binding sites ...
YANG, CHIH-HSIN;HUANG, CHING-JU;YANG, CHAO-SHUN;CHU, YU-CHUAN;CHENG, ANN-LII;WHANG-PENG, JACQUELINE;YANG, PAN-CHYR, 楊志新;黃靜如;楊朝順;朱玉娟;鄭安理;彭汪嘉康;楊泮池   +1 more
core   +2 more sources

Unlocking the Potential of Organoaluminum Reagents for Versatile C─C Couplings Using YPhos‐Pd Catalysts

Advanced Synthesis &Catalysis, Volume 368, Issue 18, 19 September 2026.
A general C─C cross‐coupling method employing earth‐abundant organoaluminium nucleophiles is enabled by electronically highly donating and sterically demanding ylide‐substituted phosphine (YPhos) ligands under Pd catalysis. This protocol represents an organoaluminium cross‐coupling that operates with a single catalyst system across all carbon ...
Nicolas Kaiser, Julius Busse, Ben Wichmann, Viktoria H. Gessner   +3 more
wiley   +1 more source

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

, 2010
M Tiseo, M Bartolotti, F Gelsomino, P BordiMedical Oncology Unit, University Hospital of Parma, Parma, ItalyAbstract: Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and their long-term prognosis remains poor ...
M Bartolotti, Bartolotti M., Gelsomino F., et al, M Tiseo, Tiseo M., F Gelsomino, Bordi P.   +7 more
core  

NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence

Cell Death Discovery
Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation.
Shuman Zhen, Yunlong Jia, Yan Zhao, Jiali Wang, Boyang Zheng, Tianxu Liu, Yuqing Duan, Wei Lv, Jiaqi Wang, Fan Xu, Yueping Liu, Yi Zhang, Lihua Liu   +12 more
doaj   +1 more source